Christel Renoux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4641849/publications.pdf

Version: 2024-02-01

70 papers

2,444 citations

218677 26 h-index 206112 48 g-index

70 all docs

70 docs citations

times ranked

70

3761 citing authors

#	Article	IF	CITATIONS
1	Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ: British Medical Journal, 2010, 340, c2519-c2519.	2.3	295
2	Trends in the prescription of novel oral anticoagulants in UK primary care. British Journal of Clinical Pharmacology, 2017, 83, 2096-2106.	2.4	199
3	Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. JAMA Psychiatry, 2019, 76, 409.	11.0	175
4	Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. Journal of Thrombosis and Haemostasis, 2010, 8, 979-986.	3.8	163
5	Association of Selective Serotonin Reuptake Inhibitors With the Risk for Spontaneous Intracranial Hemorrhage. JAMA Neurology, 2017, 74, 173.	9.0	104
6	Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. European Heart Journal, 2014, 35, 1881-1887.	2.2	96
7	Prescribing trends of attentionâ€deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995–2015. British Journal of Clinical Pharmacology, 2016, 82, 858-868.	2.4	92
8	Time-window Bias in Case-control Studies. Epidemiology, 2011, 22, 228-231.	2.7	91
9	Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017. JAMA - Journal of the American Medical Association, 2018, 320, 2149.	7.4	90
10	Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ: British Medical Journal, 2018, 360, k872.	2.3	89
11	Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ: British Medical Journal, 2017, 359, j4323.	2.3	77
12	Confounding by Pre-Morbid Functional Status in Studies of Apparent Sex Differences in Severity and Outcome of Stroke. Stroke, 2017, 48, 2731-2738.	2.0	56
13	Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism. Pharmacoepidemiology and Drug Safety, 2017, 26, 554-560.	1.9	44
14	Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. BMJ Open, 2018, 8, e018180.	1.9	44
15	Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology, 2019, 58, 683-691.	1.9	38
16	Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies. CNS Drugs, 2015, 29, 985-998.	5.9	37
17	Dopamine agonist use and the risk of heart failure. Pharmacoepidemiology and Drug Safety, 2012, 21, 34-41.	1.9	36
18	Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort study. BMJ Open, 2015, 5, e008365.	1.9	36

#	Article	IF	Citations
19	Non–Vitamin K Antagonist OralÂAnticoagulants and RiskÂofÂSeriousÂLiver Injury. Journal of the American College of Cardiology, 2018, 71, 1105-1113.	2.8	36
20	Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. British Journal of Clinical Pharmacology, 2016, 82, 461-472.	2.4	35
21	Natural History of Multiple Sclerosis: Long-Term Prognostic Factors. Neurologic Clinics, 2011, 29, 293-308.	1.8	32
22	Comparative effect of statins on the risk of incident Alzheimer disease. Neurology, 2018, 90, e179-e187.	1.1	32
23	Cardiovascular and Cerebrovascular Safety of Testosterone Replacement Therapy Among Aging Men with Low Testosterone Levels: A Cohort Study. American Journal of Medicine, 2019, 132, 1069-1077.e4.	1.5	32
24	Incidence, Mortality, and Sex Differences of Nonâ€Valvular Atrial Fibrillation: A Populationâ€Based Study. Journal of the American Heart Association, 2014, 3, e001402.	3.7	31
25	Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study. European Heart Journal, 2017, 38, ehw613.	2.2	30
26	Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ Open, 2018, 8, e019638.	1.9	28
27	Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation. American Journal of Medicine, 2019, 132, 191-199.e12.	1.5	28
28	Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review. CNS Drugs, 2018, 32, 321-334.	5.9	27
29	Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism. American Journal of Epidemiology, 2019, 188, 1666-1673.	3.4	27
30	Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder. Journal of Affective Disorders, 2020, 267, 153-170.	4.1	27
31	Degree of serotonin reuptake inhibition of antidepressants and ischemic risk. Neurology, 2019, 93, e1010-e1020.	1.1	22
32	Hormone Therapy Administration in Postmenopausal Women and Risk of Stroke. Women's Health, 2011, 7, 355-361.	1.5	18
33	Patterns of longâ€term use of nonâ€vitamin K antagonist oral anticoagulants for nonâ€valvular atrial fibrillation: Quebec observational study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1546-1554.	1.9	18
34	Data variability across Canadian administrative health databases: Differences in content, coding, and completeness. Pharmacoepidemiology and Drug Safety, 2020, 29, 68-77.	1.9	18
35	Testosterone replacement therapy and the risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials. Thrombosis Research, 2021, 199, 123-131.	1.7	18
36	Hormone replacement therapy use and the risk of stroke. Maturitas, 2008, 61, 305-309.	2.4	16

3

#	Article	IF	CITATIONS
37	Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1716-1722.	4.5	14
38	Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. Epidemiology, 2018, 29, 904-912.	2.7	14
39	Testosterone replacement therapy and the risk of stroke in men: A systematic review. Maturitas, 2017, 106, 31-37.	2.4	13
40	Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. Seminars in Arthritis and Rheumatism, 2019, 48, 1053-1058.	3.4	13
41	Infectious Disease Burden and the Risk of Alzheimer's Disease: A Population-Based Study. Journal of Alzheimer's Disease, 2021, 81, 329-338.	2.6	13
42	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression. International Journal of Cardiology, 2021, 335, 7-14.	1.7	13
43	\hat{l}^2 2-Agonists and the Incidence of Parkinson Disease. American Journal of Epidemiology, 2020, 189, 801-810.	3.4	12
44	Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study. CMAJ Open, 2020, 8, E877-E886.	2.4	10
45	Trends in new prescription of gabapentinoids and of coprescription with opioids in the 4 nations of the UK, 1993–2017. British Journal of Clinical Pharmacology, 2021, 87, 3349-3353.	2.4	10
46	Prescribing Trends of Antidepressants and Psychotropic Coprescription for Youths in UK Primary Care, 2000-2018. Journal of Affective Disorders, 2021, 287, 19-25.	4.1	10
47	Tamoxifen and the risk of Parkinsonism: a case/non-case study. European Journal of Clinical Pharmacology, 2018, 74, 1181-1184.	1.9	9
48	Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multiâ€database cohort study with metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 2589-2601.	2.4	8
49	Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study. BMC Cardiovascular Disorders, 2016, 16, 84.	1.7	7
50	Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiologic Study. Movement Disorders, 2020, 35, 176-180.	3.9	7
51	Incretinâ€Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. Clinical Pharmacology and Therapeutics, 2022, 111, 272-282.	4.7	7
52	Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study. American Journal of Epidemiology, 2022, 191, 1352-1367.	3.4	7
53	Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 389-397.	3.0	5
54	The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation. Thrombosis and Haemostasis, 2020, 120, 1384-1394.	3.4	5

#	Article	IF	CITATIONS
55	A comparison of confounder selection and adjustment methods for estimating causal effects using large healthcare databases. Pharmacoepidemiology and Drug Safety, 2021, , .	1.9	5
56	Evaluating Prevalence and Patterns of Prescribing Medications for Depression for Patients With Obesity Using Large Primary Care Data (Canadian Primary Care Sentinel Surveillance Network). Frontiers in Nutrition, 2020, 7, 24.	3.7	4
57	Difference in patterns of prescribing antidepressants known for their weight-modulating and cardiovascular side effects for patients with obesity compared to patients with normal weight. Journal of Affective Disorders, 2021, 295, 1310-1318.	4.1	4
58	Effectiveness and Safety of Apixaban versus Rivaroxaban in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus. Thrombosis and Haemostasis, 2022, 122, 1794-1803.	3.4	4
59	Association Between Intravitreal Aflibercept and Serious Non-ocular Haemorrhage Compared with Intravitreal Ranibizumab: A Multicentre Observational Cohort Study. Drug Safety, 2020, 43, 943-952.	3.2	3
60	Letter by Ganesh and Renoux Regarding Article, "Sex Differences and Functional Outcome After Intravenous Thrombolysis― Stroke, 2017, 48, e329.	2.0	2
61	Utilization and longâ€ŧerm persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. British Journal of Clinical Pharmacology, 2022, 88, 994-1009.	2.4	2
62	Aromatase inhibitors and the incidence of Parkinson disease: A populationâ€based cohort study. Cancer, 2022, 128, 2339-2347.	4.1	2
63	Privacy-preserving estimation of an optimal individualized treatment rule: a case study in maximizing time to severe depression-related outcomes. Lifetime Data Analysis, 2022, 28, 512-542.	0.9	2
64	The Reply. American Journal of Medicine, 2019, 132, e749.	1.5	1
65	Comparative Risk of Acute Kidney Injury with Oral Anticoagulant Use Among Patients with Nonvalvular Atrial Fibrillation. Blood, 2017, 130, 700-700.	1.4	1
66	Inappropriate Comparator Group in Study of Selective Serotonin Reuptake Inhibitors and Risk for Intracranial Hemorrhageâ€"Reply. JAMA Neurology, 2017, 74, 870.	9.0	0
67	Tamoxifen administration and the risk of Parkinsonism. European Journal of Clinical Pharmacology, 2019, 75, 135-136.	1.9	0
68	Reply to: Comment on "Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiological Study― Movement Disorders, 2020, 35, 376-377.	3.9	0
69	Domperidone Increases Harmful Cardiac Events in Parkinson's Disease: A Bayesian Re-Analysis of an Observational Study. Journal of Clinical Epidemiology, 2021, 140, 93-100.	5.0	0
70	Defining the duration of the dispensation of oral anticoagulants in administrative healthcare databases. Pharmacoepidemiology and Drug Safety, 2021, , .	1.9	0